The Food and Drug Administration is reportedly providing guidance and “positive feedback” for a proposed nalmefene product that will last…
Massachusetts is considering multiple proposals that, taken together, would make the landscape of overdose response increasingly hostile toward people who…
Less than two months after an investigation into deceptive marketing prompted Indivior Inc. to stop promoting its overdose antidote Opvee,…
Indivior PLC has discontinued marketing for Opvee, the opioid-overdose reversal product that the pharmaceutical company had claimed was more effective…
Indivior PLC, the pharmaceutical company that manufactures the opioid overdose antidote Opvee (nalmefene), has published new research showing that its…
On August 26, pharmaceutical manufacturer Indivior announced that it had begun supplying the Biomedical Advanced Research and Development Authority (BARDA)…
On August 7 the Food and Drug Administration approved an opioid overdose antidote developed by Purdue Pharma that contains nalmefene,…
Opvee, an opioid-overdose antidote manufactured by Indivior that was approved in 2023, has in recent weeks been slowly rolling out…